SPOTLIGHT: Astex in licensing deal with Glaxo

Astex Therapeutics pocketed an unspecified upfront payment in a licensing deal with GlaxoSmithKline. Glaxo won a nonexclusive license for Astex's cytochrome P450 intellectual property. Cytochromes P450 are drug-metabolizing enzymes. Release

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.